Acadia Pharmaceuticals Patent-Cliff Exposure & CMS Drug Spending Portfolio

Acadia Pharmaceuticals (San Diego, CA): 3 reconciled FDA prescription therapies (71.9% 2025 to 2030 cliff risk), $932.0M 2024 CMS Part D & Medicaid spend, and 3 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterSan Diego, CA
Reconciled FDA Portfolio Therapies3
2025 to 2030 Patent-Cliff Revenue Exposure71.9%
Primary Portfolio LOE Date2037-01-01
2024 CMS Total Public Spend$932.0M
2024 Medicare Part D Spend$697.4M
2024 Medicaid Spend$234.6M
California HCAI SB 17 Filings3 WAC filings (max 37.3% 2-yr change)